Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from Karyopharm Therapeutics, Inc.

Expert Illustrations & Commentaries: Exploring the Rationale and Application of XPO1 Inhibitors in Hematologic Malignancies

Release Date: October 29, 2021
Expiration Date: October 29, 2022

Activity Overview

Patients with relapsed/refractory (RR) diffuse large B-cell lymphoma (DLBCL) or RR multiple myeloma (RR MM) who have been exposed to multiple lines of treatment have few effective therapies available. One new therapeutic strategy is to target nuclear transport proteins, called exportins (XPOs), that inhibit the passage of tumor-promoting proteins across the nuclear membrane of cancer cells and lead to apoptosis of malignant cells.
This Expert Illustrations and Commentaries program will explore the mechanism of action of available and emerging therapies in patients with RR DLBCL or RR MM. This activity includes expert discussions of clinical trial data, clinical applications of this information, a review of potential adverse effects associated with use of these therapies, and the role of the multidisciplinary team in treating patients with these hematologic malignancies.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Karyopharm Therapeutics, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This activity is directed toward medical oncologists and hematologist/oncologists who treat or manage patients with hematologic malignancies. Other oncology health care professionals, including nurses and pharmacists, involved in the management of patients with hematologic malignancies are invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Illustrate the role of exportins (XPOs) on tumorigenesis in hematological malignancy settings in the context of their participation in key signal transduction pathways, oncogenes, and tumor-suppressor genes
  • Explain the mechanistic rationale for the use of XPO inhibition in the management of hematologic malignancies, including the targeting of cancer proteins by these agents, and how these approaches may act synergistically in combination and overcome treatment resistance
  • Evaluate efficacy and safety profiles from clinical trials that have evaluated XPO inhibition approaches among patients with diffuse large B-cell lymphoma and multiple myeloma
  • Describe treatment-related toxicities associated with XPO inhibitors and their practical management in contemporary clinical practice

Faculty, Staff, and Plannrs’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities

Program Chair

Irene Ghobrial, MD
Irene Ghobrial, MD
Professor of Medicine
Harvard Medical School
Director, Clinical Investigator Program
Lavine Family Chair for Preventative Cancer Therapies
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Consultant: GlaxoSmithKline, Sanofi, Janssen Pharmaceuticals, Takeda Pharmaceutical Company, Celgene Corporation, Karyopharm Therapeutics, AbbVie, GNS Healthcare, Cellectar Biosciences, Medscape, Genentech/F. Hoffman-La Roche, Adaptive Biotechnologies, Bristol Myers Squibb, Aptitude Medical Systems, Curio Biotech, Oncopeptides.


Sarah Rutherford, MD
Sarah Rutherford, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Weill Cornell Medicine
New York, NY

Disclosures: Grant/Research Support: Genentech/F. Hoffmann-La Roche, Karyopharm Therapeutics; Other: received payment from Bristol Myers Squibb and Janssen Pharmaceuticals for presentations.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By